Clinical Manifestations, Tumor Associations, and Long-Term Outcomes of Anti-KLHL11 Encephalitis
Anti-KLHL11 encephalitis is rare, lethal in 1 of 3 patients within a year, and linked to seminoma in nearly a third of cases.
Journal: Neurology: Neuroimmunology & Neuroinflammation | Published: 2026-05-29 | Type: Retrospective + prospective case series | PMID:42214057Authors: Jin Mengzhi et al. — Department of Neurology, Erasmus University Medical Center, Rotterdam
Funding/COI: Not listed
Summary
Anti-KLHL11 encephalitis is a paraneoplastic syndrome — a brain disease triggered by the immune system's response to a tumor, most classically testicular seminoma. This single-center Dutch study screened over 1,300 patients over a decade and found only 17 cases, underscoring how rare the condition is. Outcomes were grim: six patients died within 12 months, split evenly between encephalitis and cancer as the cause of death.
Claims
17 anti-KLHL11 encephalitis patients identified from 1,361 tested (serum and/or CSF) — a yield of roughly 1.2%
Median age 59 years; 71% male
Most common neurological presentations: cerebellar ataxia (71%), brainstem encephalitis (71%), opsoclonus-myoclonus syndrome (47%), limbic encephalitis (18%)
Tumor found in 59% of patients: seminoma in 5 (29%), renal cell carcinoma and urothelial carcinoma in 1 each (6% each), ovarian teratoma in 1 (6%), small-cell lung cancer in 1 (6%), carcinoma of unknown primary in 1 (6%)
MRI abnormal in 47%; abnormalities included rhombencephalon T2/FLAIR signal (18%), limbic hyperintensity (24%), cerebellar atrophy (12%)
88% received first-line immunotherapy; 35% also required second-line agents
67% achieved improvement or stabilization; 6 patients (35%) died within 12 months
Median follow-up was 20 months (range 1.5–180)
Study Quality
Seventeen patients. That is the entire evidence base. Drawn from a tertiary referral center with a decade of testing and a novel cell-based antibody assay, this is a case series dressed in retrospective-plus-prospective clothing — not a cohort study in any meaningful epidemiological sense. The testing population (n=1,361) was pre-selected for "clinical features or tumors that could be associated," introducing substantial ascertainment bias; the true prevalence in unselected populations is unknowable from this data.
That said, for an extremely rare syndrome first described only in recent years, a case series of 17 is actually a meaningful contribution to the literature. The authors describe clinical phenotypes, tumor associations, treatment responses, and survival in more granular detail than prior reports. The prospective screening component (post-July 2020) is a methodological strength compared to purely retrospective registries.
Red Flags
n=17 — underpowered for any statistical inference; reported percentages are misleading precision (71% = 12 people)
Single center, single country; selection bias from referral patterns at a specialist center
Funding and conflicts of interest not disclosed — a notable omission for a paper with potential diagnostic implications
Retrospective data for the majority of the cohort (2010–2020); chart-based outcome ascertainment
No standardized treatment protocol; immunotherapy regimens varied across patients, making treatment-response data uninterpretable
Median follow-up of 20 months is short for a condition with multi-year morbidity
"Improvement or stabilization" is a composite endpoint that obscures the magnitude of neurological recovery
Strengths
Largest reported series of anti-KLHL11 encephalitis to date, given the condition's rarity
Expands the recognized tumor spectrum beyond the original seminoma-only description to include renal cell carcinoma, urothelial carcinoma, ovarian teratoma, and small-cell lung cancer
Concurrent antibody data (NMDAR, GFAP, CASPR2) adds nuance for cases with overlapping autoimmune syndromes
Long tail of follow-up (one patient followed 180 months) captures late outcomes rarely reported in case series
Prospective screening arm suggests the authors are building toward a registry — that work will eventually matter
Verdict
This paper's main value is descriptive: it catalogs what anti-KLHL11 encephalitis looks like and, critically, tells urologists and oncologists that the tumor list is longer than previously thought. A man presenting with cerebellar ataxia after a seminoma diagnosis has a specific, named syndrome that clinicians should now test for. The 35% mortality within 12 months gives that urgency real weight. As science, the n=17 makes it a hypothesis-generating case series, not a definitive clinical guide — treat the percentages as rough signal, not evidence.